We are excited to announce that CanVirex has moved forward in the development of its lead candidate Mevacil for the treatment of cancer. CanVirex is in preparation of a phase I/IIa trial to assess safety and tolerability of Mevacil in patients with advanced-stage solid cancers. Mevacil is a proprietary, oncolytic measles virus that encodes the …
By Stacey Smith for Pharma Tech Outlook “Cancer is a journey, but you walk the road alone. There are many places to stop along the way and get nourishment—you have to be willing to take it.” (Emily Hollenberg) These lines by Emily Hollenberg, a cancer survivor, give some semblance to the predicament of cancer patients. The …
This website is operated by
CanVirex AG
Malzgasse 9
CH – 4052
Basel
+41 61 515 0775